THE DEVELOPMENT AND VALIDATION OF A FAST STABILITY INDICATING RP-HPLC METHOD FOR QUANTIFICATION OF LUMEFANTRINE AND ITS ORGANIC IMPURITIES USING CENTRAL COMPOSITE EXPERIMENTAL DESIGN

TARAKA RAMESH G.; Y. RAJENDRA PRASAD

doi:10.22159/ijap.2023v15i3.47698

Authors

TARAKA RAMESH G. Analytical Department, Etico Lifesciences, Hyderabad, Telangana, India https://orcid.org/0000-0001-8839-9658
Y. RAJENDRA PRASAD AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, Andhra Pradesh, India

DOI:

https://doi.org/10.22159/ijap.2023v15i3.47698

Keywords:

Central composite design, Organic impurities, RP-HPLC, Forced degradation, Validation, Lumefantrine

Abstract

Objective: The objective of the present study was to develop and validate a stability indicating RP-HPLC method for Lumefantrine (LF) and its organic impurities using a central composite design (CCD).

Methods: A specific, simple quality control friendly isocratic elution method using reverse phase HPLC was developed for quantification of Lumefantrine (LF) and its organic impurities at a wavelength of 265 nm. The chromatographic separation was achieved on the column of Thermo Hypersil ODS C18 (150x4.6 mm, 3µ) with a buffer containing 0.1percent formic acid and acetonitrile 10:90 v/v as a mobile phase with a flow rate of 1.6 ml/min at 35 °C with a run time of 10 min. Based on the preliminary trials, CCD was employed to check the effect of independent variables such as Acetonitrile ratio (A), Flow rate (B), and Column oven temperature (C). While resolution between Lumefantrine (LF) and Impurity-A (X1), Impurity-A and Impurity-B (X2), and Plate count of Lumefantrine (LF) (X3) were considered as dependent variables and statistical evaluation performed by using design expert software. The optimized conditions were validated as per ICH guidelines.

Results: The retention time of LF and its organic impurities were 1.9 min, 3.0, 4.5, and 6.4 min, respectively. Design space was established and desirability was found. LOD and LOQ for the Lumefantrine (LF) and its impurities were established with respect to test concentration. The plotted calibration curves were linear with a regression coefficient of R2>0.99, indicating that the linearity was within the limit. As a part of method validation, the parameters like Specificity with forced degradation, Linearity, Precision, Accuracy, Ruggedness, and Robustness were determined and the results were found to be within the allowable limits.

Conclusion: The method developed and validated was found to be suitable for routine analysis and to be used for the measurement of Lumefantrine and its impurities. Since there is no stability indicating the RP-HPLC method with design space was reported in the literature, there is a need to develop quantitative methods under different conditions to achieve improvement in specificity and selectivity.

Downloads

Download data is not yet available.

References

Teklemariam M, Assefa A, Kassa M, Mohammed H, Mamo H. Therapeutic efficacy of artemether-lumefantrine against uncomplicated plasmodium falciparum malaria in a high-transmission area in northwest ethiopia. Plos One. 2017;12(4):e0176004. doi: 10.1371/journal.pone.0176004. PMID 28445503.

Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411-23. doi: 10.1056/NEJMoa1314981, PMID 25075834.

Hastings IM, Watkins WM, White NJ. The evolution of drug–resistant malaria: the role of drug elimination half–life. Philos Trans R Soc Lond B Biol Sci. 2002;357(1420):505-19. doi: 10.1098/rstb.2001.1036, PMID 12028788.

Färnert A, Ursing J, Tolfvenstam T, Rono J, Karlsson L, Sparrelid E. Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with plasmodium falciparum malaria after returning from tanzania. Malar J. 2012;11(1):176. doi: 10.1186/1475-2875-11-176, PMID 22632033.

Hastings I. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends Parasitol. 2011;27(2):67-72. doi: 10.1016/j.pt.2010.09.005. PMID 20971040.

Egunsola O, Oshikoya KA. Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review. Malar J. 2013;12(1):385. doi: 10.1186/1475-2875-12-385, PMID 24175945.

Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother. 2007;8(1):75-94. doi: 10.1517/14656566.8.1.75, PMID 17163809.

Khan A, Agrawal S. Formulation and evaluation of lumefantrine capsule prepared by using liquisolid technique. Int J Curr Pharm Sci. 2018;10(2):43. doi: 10.22159/ijcpr.2018v10i2.25836.

Lefèvre G, Thomsen MS. Clinical pharmacokinetics of artemether and lumefantrine (Riamet??). Clin Drug Investig. 1999;18(6):467-80. doi: 10.2165/00044011-199918060-00006.

Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A. In vivo selection of plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005;191(6):1014-7. doi: 10.1086/427997, PMID 15717281.

International conference for harmonization. ICH harmonised tripartite guideline. Impurities in new drug products. Vol. Q3B(R2); 2006.

International conference for harmonization. ICH harmonised tripartite guideline. Stability testing of new drug substances and products. Vol. Q1A(R2); 2003.

Suleman S, Verheust Y, Dumoulin A, Wynendaele E, D’Hondt M, Vandercruyssen K. Gas chromatographic method for the determination of lumefantrine in antimalarial finished pharmaceutical products. J Food Drug Anal. 2015;23(3):552-9. doi: 10.1016/j.jfda.2015.03.004. PMID 28911715.

Pratiksha S, Jenish M, Zarna D, Rona D. QbD Approach for stability indicating hplc method for determination of artemether and lumefantrine in combined dosage form. IJDRA. 2017;5(4):44-59. doi: 10.22270/ijdra.v5i4.209.

Sukanya B, Mohan Goud V, Anitha P. Stability indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of artemether and lumefantrine in bulk and pharmaceutical dosage form. J Drug Delivery Ther 2019;9(2):217-21. doi: 10.22270/jddt.v9i2.2408.

Marques MBF, Araujo BCR, Fernandes C, Yoshida MI, Mussel WN, Sebastiao RCO. Kinetics of lumefantrine thermal decomposition employing isoconversional models and artificial neural network. J Braz Chem Soc. 2020;31(3):512. doi: 10.21577/0103-5053.20190211.

Pingale SG, Mangaonkar KV. Quantification of lumefantrine in human plasma using lc-ms/ms and its application to a bioequivalence study. J Pharm (Cairo). 2013;2013(1):437697. doi: 10.1155/2013/437697, PMID 26555980.

Shamshad K, Umer FG, Hamid M, Asma Z, Mubarik S. High-performance liquid chromatography method development and an innovative technique for validation of artemether and lumefantrine oral dry suspension. Biomed J Sci Tech Res. 2020;32(2):34. doi: 10.26717/BJSTR.2020.32.005234.

Rao VP, Rambabu C. Validated reverse phase high performance liquid chromatographic method for the simultaneous determination of artemether and lumefantrine in fixed combined dosage form. Asian J Pharm Clin Res. 2016;10(3):159. doi: 10.22159/ajpcr.2017.v10i3.15930.

International conference for harmonization. ICH harmonized tripartite guideline. Validation Anal Proc Text Methodol. Vol. Q2(R1); 2005.

Naresh P, Kumar KV. Leflunomide tablet formulation: development and validation of an RP-HPLC technique. Int J Pharm Pharm Sci. 2022;15(1):16-21. doi: 10.22159/ijpps.2023v15i1.46505.

De AK, Bera T. Analytical method development, validation and stability studies by RP-HPLC method for simultaneous estimation of andrographolide and curcumin in co-encapsulated nanostructured lipid carrier drug delivery system. Int J App Pharm. 2021;13(10):73-86. doi: 10.22159/ijap.2021v13i5.42181.

Ramesh D, Habibuddin M. Development and validation of RP-HPLC method for the determination of alvimopan in rat plasma. Int J Pharm Pharm Sci. 2018;10(10):124. doi: 10.22159/ijpps.2018v10i10.29001.

Sesharao M, Madhavarao V. A new validated simultaneous reversed-phase high-performance liquid chromatography assay method for estimation of two flavones (baicalein and chrysin) in api drugs. Asian J Pharm Clin Res 2018;11(1). doi: 10.22159/ajpcr.2018.v11i1.21174.

Rayudu S, Manoranjani M, Sekhara Reddy DR. Analytical method development and validation of dexmethylphenidate and serdexmethylphenidate by using RP-HPLC in bulk and pharmaceutical dosage form. Int J App Pharm. 2022;14(2):110-5. doi: 10.22159/ijap.2022v14i2.43515.

Sura RS, Cvs S, Rachamalla SS. Bioanalytical RP-HPLC method development and validation of clopidogrel bisulfate in Wistar rat plasma and its application to pharmacokinetic study. Int J App Pharm. 2022;14(1):106-11. doi: 10.22159/ ijap.2022v14i1.43328.

Alumuri T, Amarababu NLA, Kurnool A, Kanuparthy PR, Merugu K. Development and validation of a stability indicating related substances of atenolol and nitrendipine by RP-HPLC. Int J App Pharm. 2022;14(4):265-73. doi: 10.22159/ijap.2022v14i4.44531.

Vander Heyden Y, Jimidar M, Hund E, Niemeijer N, Peeters R, Smeyers-Verbeke J. Determination of system suitability limits with a robustness test. J Chromatogr A. 1999;845(1-2):145-54. doi: 10.1016/S0021-9673(99)00328-3.

Reddy CS, Rao BT. Development and validation of a stability indicating related substances of trandolapril by rp-hplc and its degradation. Int J App Pharm. 2021;13(5):115-21. doi: 10.22159/ijap.2021v13i5.42113.

Tabassum R, Rizwan SH. Stability indicating analytical method development and validation for the estimation of Ruxolitinib in bulk and pharmaceutical dosage form using UPLC. Int J Pharm Pharm Sci. 2022;15(2):40-6. doi: 10.22159/ijpps.2023v15i2.46839.

Rao PV, Rao AL, Svum P. Development and validation of new stability indicating reversed-phase high-performance liquid chromatography method for simultaneous determination of metformin hydrochloride and ertugliflozin in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res 2019;12(1). doi: 10.22159/ajpcr.2019.v12i1.28938.

Rode DM, Rao NN. A review on development and validation of stability indicating HPLC methods for analysis of acidic drugs. Int J Curr Pharm Sci. 2019;11(4):22-33. doi: 10.22159/ijcpr.2019v11i4.34939.

Vessman J, Stefan RI, van Staden JF, Danzer K, Lindner W, Burns DT. Selectivity in analytical chemistry (IUPAC recommendations 2001). Pure Appl Chem. 2001;73(8):1381-6. doi: 10.1351/pac200173081381.

Rao N, Gawde KD. Method development and force degradation studies for simultaneous estimation of salbutamol sulfate, etofylline and bromhexine hydrochloride in pharmaceutical dosage form using reversed-phase high-performance liquid chromatography method. Asian J Pharm Clin Res. 2018;11(8):378. doi: 10.22159/ajpcr.2018.v11i8.26119.

Verbeken M, Suleman S, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C. Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Malar J. 2011;10(1):51. doi: 10.1186/1475-2875-10-51, PMID 21356068.

Murugesan A, Mathrusri Annapurna M. Simple quantified and validated stability indicating stress degradation studies of oral anti-diabetic agent dapagliflozin by RP-HPLC method. Int J App Pharm. 2022;14(1):231-7. doi: 10.22159/ijap.2022v14i1.43482.